1085706-55-3

Basic information

• Product Name: dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate
• Synonyms: dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate
• CAS NO: 1085706-55-3
• Molecular Weight: 806.921
• Mol File: 1085706-55-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate(1085706-55-3)
• EPA Substance Registry System: dimethyl-(1R,1'R)-2,2'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate(1085706-55-3)

Safety Data

• Hazardous Substances Data: 1085706-55-3(Hazardous Substances Data)

Upstream product

• 766-99-4 1-ethynyl-4-iodobenzene 
• 1085706-41-7 (2S,2'S)-tert-butyl 2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1H-pyrazole-5,3-diyl))dipyrrolidine-1-carboxylate 
• 1085706-38-2 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-pyrazol-3-yl)pyrrolidine-1-carboxylate 
• 1085706-40-6 (S)-tert-butyl 2-(5-(4-iodophenyl)-1H-pyrazol-3-yl)pyrrolidine-1-carboxylate 
• 1085706-39-3 (S)-tert-butyl 2-(3-(4-iodophenyl)propioloyl)pyrrolidine-1-carboxylate 
• 1085706-37-1 (S)-tert-butyl 2-(3-(4-bromophenyl)propioloyl)pyrrolidine-1-carboxylate 
• 1007877-76-0 (R)-tert-butyl 2-(methoxycarbonylamino)-2-phenylacetate 
• 766-96-1 4-bromo-1-ethynylbenzene 
• 50890-96-5 (2R)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that ', at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.